The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer

Chiranjib Chakraborty; Ashish Ranjan Sharma; Garima Sharma; Bimal Kumar Sarkar; Sang-Soo Lee

doi:10.18632/oncotarget.24309

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer

Chiranjib Chakraborty _, Ashish Ranjan Sharma, Garima Sharma, Bimal Kumar Sarkar and Sang-Soo Lee

PDF | HTML | How to cite

Oncotarget. 2018; 9:10164-10174. https://doi.org/10.18632/oncotarget.24309

Metrics: PDF 2745 views | HTML 4604 views | ?

Abstract

Chiranjib Chakraborty1,2,*, Ashish Ranjan Sharma1,*, Garima Sharma1, Bimal Kumar Sarkar3 and Sang-Soo Lee1

1Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon 24252, Republic of Korea

2Department of Bioinformatics, School of Computer Sciences, Galgotias University, Greater Noida 203201, Uttar Pradesh, India

3Department of Physics, School of Basic and Applied Science, Galgotias University, Greater Noida 203201, Uttar Pradesh, India

*These authors contributed equally to this work

Correspondence to:

Chiranjib Chakraborty, email: [email protected]

Sang-Soo Lee, email: [email protected]

Keywords: miRNA; combination therapy; chemotherapeutic agents; cancer; next-generation therapy

Received: September 13, 2017 Accepted: December 11, 2017 Published: January 23, 2018

ABSTRACT

Medical practitioners are recommending combination therapy in cancer for its various advantages. Combination therapy increases the efficacy of treatment due to its synergistic effects in cancer treatment. In this post-genomic era, microRNAs (miRNAs) are receiving attention for their role in human disease and disease therapy. In this review, we discuss the combination of miRNAs and chemotherapeutic agents for cancer treatment. Moreover, we attempted to portray the role of miRNAs in cancer therapy; outline combination therapy, especially chemo-combination therapy, and discuss the basis for miRNA-based chemo-combination therapies and chemo-combination therapy with miRNA for cancer treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24309

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer

Abstract